



Viamet Pharmaceuticals Announces Presentations at ID Week 2016 on Novel Antifungal Compounds VT-1161 and VT-1129

Data Highlights Company's Robust Antifungal Pipeline

October 27, 2016, Research Triangle Park, North Carolina – Viamet Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, today announced that data from preclinical studies of the novel antifungal compounds VT-1161 and VT-1129 will be presented on Friday, October 28th at ID Week 2016, in New Orleans, Louisiana. VT-1161 and VT-1129 are orally-administered inhibitors of fungal CYP51. VT-1161 is currently in Phase 2 clinical development for the treatment of recurrent vulvovaginal candidiasis and onychomycosis. VT-1129 is currently in Phase 1 clinical development for the treatment of cryptococcal meningitis.

“Data generated by our collaborators at Duke University and the National Institutes of Health highlight the exceptional potency of VT-1161 and VT-1129 against *Candida* species resistant to many current antifungal therapies, including *Candida krusei* and fungal pathogens isolated from patients suffering from chronic mucocutaneous candidiasis,” said Dr. Robert Schotzinger, M.D., Ph.D., CEO of Viamet. “The increasing resistance of fungal pathogens to current therapies poses a significant threat and the development of new antifungal agents is a clear global priority. Viamet is dedicated to the development of effective and safe therapies that target a wide range of fungal pathogens and therapeutic indications. We look forward to further discussion on the need for new antifungal therapies at the conference and to advancing the development of our antifungal pipeline.”

Presentation details:

Friday, October 28: Session 163 – Mycology – There's a Fungus Among Us: Treatment (12:30 p.m. – 2:00 p.m. CDT, New Orleans Convention Center, Poster Hall)

Presentation Number: 1635

Authors: J.V. Desai, et. al.

Presentation Title: VT-1129 and VT-1161 have *In Vitro* Activity Against *Candida* Isolates from Patients with Chronic Mucocutaneous Candidiasis

Presentation Number: 1638

Authors: W.A. Schell, et. al.

Presentation Title: Investigational CYP51 Inhibitors VT-1161 and VT-1129 Show Strong Activity *In Vitro* Against *Candida krusei*

About VT-1161

VT-1161 is a potent and selective, orally-administered inhibitor of fungal CYP51 currently in Phase 2b clinical trials for the treatment of recurrent vulvovaginal candidiasis (RVVC) and onychomycosis. VT-1161 blocks the production of ergosterol, an essential component of the fungal cell membrane. In preclinical and clinical studies, VT-1161 has demonstrated broad-spectrum activity against both *Candida* and dermatophyte species, including those species that cause RVVC and onychomycosis. Given the clinical and pre-clinical profile of VT-1161, the Company believes that it may avoid the side effects that limit the use of current oral antifungal therapies, such as liver toxicity and drug-drug interactions. The U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) and Fast Track designations to VT-1161 for the treatment of RVVC. There are no approved therapies in the United States for RVVC.

About VT-1129

VT-1129 is a potent and selective, orally-administered inhibitor of fungal CYP51 currently in Phase 1 clinical trials for the treatment of cryptococcal meningitis, a life-threatening fungal infection of the brain and the spinal

cord. VT-1161 blocks the production of ergosterol, an essential component of the fungal cell membrane. Oral VT-1129 has demonstrated very high potency against *Cryptococcus* species, achieves high concentrations within the central nervous system, and markedly improves survival in preclinical models of cryptococcal meningitis. The U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) and orphan designations to VT-1129 for the treatment of cryptococcal meningitis.

About Viamet (www.viamet.com)

Viamet discovers and develops breakthrough therapies based on our leadership in metalloenzyme chemistry and biology. Our clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. We also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. Focusing on the needs of patients and clinicians, we design our drug candidates to achieve superior safety and efficacy profiles compared to currently marketed drugs.

Contact:

Blair McCarthy Atkinson

MacDougal Biomedical Communications Direct:

+1 812 454 6257

Main: +1 781 235 3060

batkinson@macbiocom.com

This press release includes forward-looking statements. Actual results may vary materially from these statements. There are many important risks affecting Viamet's business, including that clinical trials may not be commenced, or if commenced, may not be successful, regulatory approvals may not be obtained and approved products, if any, may not achieve commercial success. The Viamet group of companies includes Viamet Pharmaceuticals Holdings, LLC and its operating subsidiaries, Viamet Pharmaceuticals (NC), Inc., Viamet Pharmaceuticals (Bermuda), Ltd., VPS-2, Inc. and VPS-3, Inc. The Viamet group of companies is based in the Research Triangle Park region of North Carolina, USA.